Lakefront Biotherapeutics
- Market cap
- 1.96B
- P/E (TTM)i
- 2.96
- P/Bi
- 0.54
- EPSi
- 5.45
- Div yieldi
- 0.00%
- 52W posi
- 41%
Anonymous reader poll. Unscientific, not investment advice.
Lakefront Biotherapeutics shares were changing hands at 30.00, up 2.32% on the day. Its market capitalisation is about 1.96B, the #2803 most valuable US-listed company we track. Valuation-wise, the P/E sits at 2.88, 81% below the five-year average of 14.77. Wall Street's 2-analyst consensus lands on Buy, with a price target averaging 37.50 (+25% from here). The shares sit 41% of the way up their 52-week range of 25.68 to 36.24.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Recent price momentum is -8.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 5.2% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 29.32
- Open
- 29.09
- Day range
- 28.96 - 30.05
- Avg price
- 29.83
- Volume
- 362.25K
- Turnover
- 10.81M
- Turnover ratei
- 1.51%
- Volume ratioi
- 1.07
- Amplitudei
- 3.72%
- 52-week rangei
- 25.68 - 36.24
Valuation
- P/Ei
- 5.50
- P/E (TTM)i
- 2.96
- P/Bi
- 0.54
- EPSi
- 5.45
- Book value / shi
- 55.80
- Net profit
- 357.02M
- Net assets
- 3.65B
Share structure
- Market cap
- 1.96B
- Float capi
- 719.38M
- Shares out
- 65.48M
- Float sharesi
- 23.98M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
17.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+4.34M net over the window
Short interest
- Shares short
- 3.41M
- % of floati
- 5.21%
- Days to coveri
- 12.35
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Lakefront Biotherapeutics (LKFT)?
Lakefront Biotherapeutics last traded at 30.00. The quote on this page refreshes every few seconds while US markets are open.
What is Lakefront Biotherapeutics's market cap?
About 1.96B.
What is the P/E ratio of Lakefront Biotherapeutics?
The trailing twelve-month P/E is 2.96, below its own 5-year average of 14.77 — toward the top of its historical range (67.55% percentile). See the Valuation tab for the full history.
Does Lakefront Biotherapeutics pay a dividend?
Lakefront Biotherapeutics does not currently pay a regular dividend.
Is Lakefront Biotherapeutics a buy according to analysts?
The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 37.50, which implies 25.0% upside from the current price. This is not investment advice.
What is Lakefront Biotherapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Lakefront Biotherapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 04:22:05 · For reference only, not investment advice and not tailored to your situation.